Hideki Shimodaira
Overview
Explore the profile of Hideki Shimodaira including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
905
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yanagita M, Muto S, Nishiyama H, Ando Y, Hirata S, Doi K, et al.
Clin Exp Nephrol
. 2023 Dec;
28(2):123-124.
PMID: 38070021
No abstract available.
2.
Yanagita M, Muto S, Nishiyama H, Ando Y, Hirata S, Doi K, et al.
Clin Exp Nephrol
. 2023 Oct;
28(2):85-122.
PMID: 37878114
No abstract available.
3.
Ando Y, Nishiyama H, Shimodaira H, Takano N, Sakaida E, Matsumoto K, et al.
Int J Clin Oncol
. 2023 Jul;
28(10):1315-1332.
PMID: 37453935
Cisplatin should be administered with diuretics and Magnesium supplementation under adequate hydration to avoid renal impairment. Patients should be evaluated for eGFR (estimated glomerular filtration rate) during the treatment with...
4.
Takahashi S, Ouchi K, Sakamoto Y, Mori T, Shimodaira H, Takahashi M, et al.
J Gastrointest Oncol
. 2023 May;
14(2):676-691.
PMID: 37201044
Background: Little is known about the biweekly combined use of cetuximab and chemotherapy as second-line treatment of metastatic colorectal cancer (mCRC). Recently, DNA methylation status has been reported to be...
5.
Yoshioka T, Takahashi M, Sakamoto Y, Okita A, Fukui T, Murakawa Y, et al.
Anticancer Res
. 2022 Mar;
42(4):2009-2015.
PMID: 35347022
Background/aim: This phase II study assessed the efficacy of capecitabine plus cisplatin in patients with advanced gastric cancer refractory to adjuvant S-1. Patients And Methods: This single-arm, open-label, multicenter, phase...
6.
Tomita N, Ishida H, Tanakaya K, Yamaguchi T, Kumamoto K, Tanaka T, et al.
Int J Clin Oncol
. 2021 Jun;
26(8):1353-1419.
PMID: 34185173
Hereditary colorectal cancer (HCRC) accounts for < 5% of all colorectal cancer cases. Some of the unique characteristics commonly encountered in HCRC cases include early age of onset, synchronous/metachronous cancer...
7.
Takahashi M, Sakamoto Y, Otsuka K, Kanbe M, Ohori H, Shindo Y, et al.
Tohoku J Exp Med
. 2021 May;
254(1):49-55.
PMID: 34053967
Whether trastuzumab use beyond disease progression is beneficial in second-line treatment for patients with unresectable human epidermal growth factor receptor 2 (HER2)-positive gastric cancer remains to be elucidated. We conducted...
8.
Takahashi M, Sakamoto Y, Ohori H, Tsuji Y, Kuroki M, Kato S, et al.
Cancer Chemother Pharmacol
. 2021 May;
88(3):393-402.
PMID: 34028598
Purpose: The current study aimed to determine the efficacy of trifluridine/tipiracil for elderly patients with advanced colorectal cancer. Methods: This single-arm, open-label, multicenter, phase II study included elderly patients aged...
9.
Ishida H, Yamaguchi T, Tanakaya K, Akagi K, Inoue Y, Kumamoto K, et al.
J Anus Rectum Colon
. 2019 Nov;
2(Suppl I):S1-S51.
PMID: 31773066
Hereditary colorectal cancer accounts for less than 5% of all colorectal cancer cases. Some of the unique characteristics that are commonly encountered in cases of hereditary colorectal cancer include early...
10.
Sugiyama S, Ishizuka M, Takahashi M, Komine K, Imai H, Saijo K, et al.
Int Cancer Conf J
. 2019 Jun;
5(4):163-167.
PMID: 31149447
A 60-year-old woman was admitted to a medical clinic because of epigastric pain. Esophagogastroduodenoscopy revealed a submucosal tumor in the upper gastric corpus and, the tumor was subsequently resected using...